IgA immunotherapy of tuberculosis. (360G-Wellcome-082444_B_07_Z)
of 2E9/IgA1 to modulate infection with tubercle bacilli of monocyte-derived cells and macrophage cell lines. In addition, we will investigate the capacity of 2E9/IgA1 to mediate ADCC against Mtb infected macrophages. The protective effect of passive IgA therapy in vivo will be assessed in mice transgenic for human FcalphaRI/CD89. Protection will be optimized by co-inoculation of rIFNgamma and anti-IL-4 antibody. To develop a deeper understanding of the mechanisms involved, we will investigatethe influence of 2E9/IgA1 on Mtb-induced phagosomal membrane changes using confocal microscopy and real time imaging, and we will assess the 2E9/IgA1's ability toenhance antigen presentation.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
| Amount Awarded | 10762 |
| Applicant Surname | Woof |
| Approval Committee | Immunology and Infectious Disease Funding Committee |
| Award Date | 2007-04-24T00:00:00+00:00 |
| Financial Year | 2006/07 |
| Grant Programme: Title | Project Grant |
| Internal ID | 082444/B/07/Z |
| Lead Applicant | Prof Jennifer Woof |
| Other Applicant(s) | Dr Rajko Reljic |
| Partnership Value | 10762 |
| Planned Dates: End Date | 2009-09-30T00:00:00+00:00 |
| Planned Dates: Start Date | 2007-07-01T00:00:00+00:00 |
| Recipient Org: Country | United Kingdom |
| Region | Scotland |